Previous research has shown that activators of PPARγ and PGC‐1α can protect against diabetic nephropathy and suppress inflammation by inhibiting the NF‐κB signalling pathway, both in diabetic mice and in a human proximal tubular cell line [S2]. This evidence concerns the gene NFKB1 and diabetic kidney disease.